Literature DB >> 14614673

Impact of mannose-binding lectin on susceptibility to infectious diseases.

Damon P Eisen1, Robyn M Minchinton.   

Abstract

When the adaptive immune response is either immature or compromised, the innate immune system constitutes the principle defense against infection. Mannose-binding lectin (MBL) is a C-type serum lectin that plays a central role in the innate immune response. MBL binds microbial surface carbohydrates and mediates opsonophagocytosis directly and by activation of the lectin complement pathway. A wide variety of clinical isolates of bacteria, fungi, viruses, and parasites are bound by MBL. Three polymorphisms in the structural gene MBL2) and 2 promoter gene polymorphisms are commonly found that result in production of low serum levels of MBL. Clinical studies have shown that MBL insufficiency is associated with bacterial infection in patients with neutropenia and meningococcal sepsis. Low MBL levels appear to predispose persons to HIV infection. Numerous other potential infectious disease associations have been described. Therapy to supplement low MBL levels is being explored using either plasma-derived or recombinant material.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14614673     DOI: 10.1086/379324

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  136 in total

1.  Plasma proteome of severe acute respiratory syndrome analyzed by two-dimensional gel electrophoresis and mass spectrometry.

Authors:  Jenn-Han Chen; Yu-Wang Chang; Chen-Wen Yao; Tzong-Shi Chiueh; Su-Chin Huang; Ko-Yi Chien; An Chen; Feng-Yee Chang; Chi-Huey Wong; Yu-Ju Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-30       Impact factor: 11.205

Review 2.  The role of the complement system in innate immunity.

Authors:  Horea Rus; Cornelia Cudrici; Florin Niculescu
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 3.  From evolutionary genetics to human immunology: how selection shapes host defence genes.

Authors:  Luis B Barreiro; Lluís Quintana-Murci
Journal:  Nat Rev Genet       Date:  2009-12-01       Impact factor: 53.242

Review 4.  Therapeutic potential of complement modulation.

Authors:  Eric Wagner; Michael M Frank
Journal:  Nat Rev Drug Discov       Date:  2009-12-04       Impact factor: 84.694

5.  An analysis of genetic variation across the MBL2 locus in Dutch Caucasians indicates that 3' haplotypes could modify circulating levels of mannose-binding lectin.

Authors:  Toralf Bernig; Willemijn Breunis; Nannette Brouwer; Amy Hutchinson; Robert Welch; Dirk Roos; Taco Kuijpers; Stephen Chanock
Journal:  Hum Genet       Date:  2005-10-06       Impact factor: 4.132

6.  Functional variations in MBL2 gene are associated with cutaneous leishmaniasis in the Amazonas state of Brazil.

Authors:  F J de Araujo; T G Mesquita; L D O da Silva; S A de Almeida; W de S Vital; A Chrusciak-Talhari; J A de O Guerra; S Talhari; R Ramasawmy
Journal:  Genes Immun       Date:  2015-03-12       Impact factor: 2.676

7.  Clinical significance of mannose-binding lectin expression in thyroid carcinoma tissues.

Authors:  Yifang Lu; Guogui Sun; Geling Liu; Yanping Shi; Ying Han; Fang Yu; Xiuxiu Xiang; Weijuan Li; Hongzhen Xiao; Xiuling Liu; Sha Li
Journal:  Pathol Oncol Res       Date:  2012-12-19       Impact factor: 3.201

Review 8.  Update on gene modifiers in cystic fibrosis.

Authors:  Joseph M Collaco; Garry R Cutting
Journal:  Curr Opin Pulm Med       Date:  2008-11       Impact factor: 3.155

9.  Chicken mannose-binding lectin (MBL) gene variants with influence on MBL serum concentrations.

Authors:  Rikke M Kjærup; Liselotte R Norup; Karsten Skjødt; Tina S Dalgaard; Helle R Juul-Madsen
Journal:  Immunogenetics       Date:  2013-03-02       Impact factor: 2.846

10.  An experimental verification of the predicted effects of promoter TATA-box polymorphisms associated with human diseases on interactions between the TATA boxes and TATA-binding protein.

Authors:  Ludmila Savinkova; Irina Drachkova; Tatyana Arshinova; Petr Ponomarenko; Mikhail Ponomarenko; Nikolay Kolchanov
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.